Pages that link to "Q33677118"

The following pages link to Body composition changes during androgen deprivation therapy for prostate cancer: a 2-year prospective study (Q33677118):

Displaying 31 items.

• Adverse effects of androgen deprivation therapy in men with prostate cancer: a focus on metabolic and cardiovascular complications (Q26852930) (← links)
• Muscle function, physical performance and body composition changes in men with prostate cancer undergoing androgen deprivation therapy (Q26864943) (← links)
• Update on the management of prostate cancer with goserelin acetate: patient perspectives (Q34418403) (← links)
• Review: Risk stratification in the hormonal treatment of patients with prostate cancer (Q35076189) (← links)
• An update on the changing indications for androgen deprivation therapy for prostate cancer (Q35549863) (← links)
• Sarcopenia during androgen-deprivation therapy for prostate cancer (Q36212442) (← links)
• Strength training induces muscle hypertrophy and functional gains in black prostate cancer patients despite androgen deprivation therapy (Q36672192) (← links)
• Changes in physical functioning and muscle strength in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison. (Q36723162) (← links)
• The effect of strength training on muscle cellular stress in prostate cancer patients on ADT. (Q37212961) (← links)
• The effect of androgen deprivation therapy on body composition in men with prostate cancer: systematic review and meta-analysis. (Q37678989) (← links)
• Androgen deprivation therapy for prostate cancer: implications for cardiometabolic clinical care (Q37990639) (← links)
• A critical evaluation of body composition modalities used to assess adipose and skeletal muscle tissue in cancer (Q38021854) (← links)
• Testosterone and obesity (Q38485746) (← links)
• Assessment of anticancer-treatment outcome in patients with metastatic castration-resistant prostate cancer-going beyond PSA and imaging, a systematic literature review. (Q38555581) (← links)
• Exercise overcome adverse effects among prostate cancer patients receiving androgen deprivation therapy: An update meta-analysis (Q38691070) (← links)
• The use of exercise interventions to overcome adverse effects of androgen deprivation therapy. (Q38817011) (← links)
• Time on androgen deprivation therapy and adaptations to exercise: secondary analysis from a 12-month randomized controlled trial in men with prostate cancer (Q40057603) (← links)
• Body composition alterations, energy expenditure and fat oxidation in elderly males suffering from prostate cancer, pre and post orchiectomy (Q41952619) (← links)
• Assessment of endothelial dysfunction by flow-mediated dilatation in men on long-term androgen deprivation therapy for prostate cancer. (Q45126569) (← links)
• Effects of strength training on body composition, physical functioning, and quality of life in prostate cancer patients during androgen deprivation therapy (Q48039587) (← links)
• Effect of androgen deprivation therapy on the contractile properties of type I and type II skeletal muscle fibres in men with non-metastatic prostate cancer. (Q48051359) (← links)
• Attenuation of Metabolic Syndrome by EPA/DHA Ethyl Esters in Testosterone-Deficient Obese Rats. (Q55515329) (← links)
• Impact of rectum and bladder anatomy in intrafractional prostate motion during hypofractionated radiation therapy (Q57452960) (← links)
• Efficacy of recreational football on bone health, body composition, and physical functioning in men with prostate cancer undergoing androgen deprivation therapy: 32-week follow-up of the FC prostate randomised controlled trial (Q59510892) (← links)
• Androgen deprivation therapy promotes an obesity-like microenvironment in periprostatic fat (Q64075912) (← links)
• Interaction between leukocyte aldo-keto reductase 1C3 activity, genotypes, biological, lifestyle and clinical features in a prostate cancer cohort from New Zealand. (Q64890581) (← links)
• Longitudinal assessment of BMI in relation to ADT use among early stage prostate cancer survivors (Q84567489) (← links)
• The Adverse Effects of Androgen Deprivation Therapy in Prostate Cancer and the Benefits and Potential Anti-oncogenic Mechanisms of Progressive Resistance Training (Q89706210) (← links)
• The clinical relevance of adiposity when assessing muscle health in men treated with androgen deprivation for prostate cancer (Q91851181) (← links)
• Feasibility of an intervention for men on androgen deprivation therapy: A research protocol (Q92471293) (← links)
• Protective effect of pharmacological castration on metabolic perturbations and cardiovascular disease in the hyperglycemic male ApoE-/-:Ins2 /Akita mouse model (Q100316325) (← links)